{"Title": "Comparative Analysis of Different Definitions of Amyloid-\u03b2 Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer", "Year": 2021, "Source": "J. Prev. Alzheimer's Dis.", "Volume": "8", "Issue": 1, "Art.No": null, "PageStart": 68, "PageEnd": 77, "CitedBy": 0, "DOI": "10.14283/jpad.2020.51", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85097215602&origin=inward", "Abstract": "\u00a9 2020, The Author(s).Amyloid-\u03b2 (A\u03b2) positivity is defined using different biomarkers and different criteria. Criteria used in symptomatic patients may conceal meaningful early A\u03b2 pathology in preclinical Alzheimer. Therefore, the description of sensitive cutoffs to study the pathophysiological changes in early stages of the Alzheimer\u2019s continuum is critical. Here, we compare different A\u03b2 classification approaches and we show their performance in detecting pathophysiological changes downstream A\u03b2 pathology. We studied 368 cognitively unimpaired individuals of the ALFA+ study, many of whom in the preclinical stage of the Alzheimer\u2019s continuum. Participants underwent A\u03b2 PET and CSF biomarkers assessment. We classified participants as A\u03b2 -positive using five approaches: (1) CSF A\u03b242 < 1098 pg/ml; (2) CSF A\u03b242/40 < 0.071; (3) A\u03b2 PET Centiloid > 12; (4) A\u03b2 PET Centiloid > 30 or (5) A\u03b2 PET Positive visual read. We assessed the correlations between A\u03b2 biomarkers and compared the prevalence of A\u03b2 positivity. We determined which approach significantly detected associations between A\u03b2 pathology and tau/neurodegeneration CSF biomarkers. We found that CSF-based approaches result in a higher A\u03b2-positive prevalence than PET-based ones. There was a higher number of discordant participants classified as CSF A\u03b2-positive but PET A\u03b2-negative than CSF A\u03b2-negative but PET A\u03b2-positive. The CSF A\u03b2 42/40 approach allowed optimal detection of significant associations with CSF p-tau and t-tau in the A\u03b2-positive group. Altogether, we highlight the need for sensitive A\u03b2 -classifications to study the preclinical Alzheimer\u2019s continuum Approaches that define A\u03b2 positivity based on optimal discrimination of symptomatic Alzheimer\u2019s disease patients may be suboptimal for the detection of early pathophysiological alterations in preclinical Alzheimer.", "AuthorKeywords": ["Alzheimer\u2019s disease", "biomarkers", "cerebrospinal fluid", "positron emission tomography", "preclinical Alzheimer"], "IndexKeywords": null, "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": null, "EID": "2-s2.0-85097215602", "SubjectAreas": [["Medicine (all)", "MEDI", "2700"]], "AuthorData": {"57213789499": {"Name": "Mil\u00e0-Alom\u00e0 M.", "AuthorID": "57213789499", "AffiliationID": "121846058", "AffiliationName": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES)"}, "57202247633": {"Name": "Salvad\u00f3 G.", "AuthorID": "57202247633", "AffiliationID": "60023506, 60000100", "AffiliationName": "IMIM (Hospital del Mar Medical Research Institute)"}, "57213595985": {"Name": "Shekari M.", "AuthorID": "57213595985", "AffiliationID": "60032942", "AffiliationName": "Universitat Pompeu Fabra"}, "55851409500": {"Name": "Grau-Rivera O.", "AuthorID": "55851409500", "AffiliationID": "60023506, 60030315", "AffiliationName": "Servei de Neurologia, Hospital del Mar"}, "6507186196": {"Name": "Sala-Vila A.", "AuthorID": "6507186196", "AffiliationID": "60023506, 60000100", "AffiliationName": "IMIM (Hospital del Mar Medical Research Institute)"}, "26967895200": {"Name": "S\u00e1nchez-Benavides G.", "AuthorID": "26967895200", "AffiliationID": "121846058", "AffiliationName": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES)"}, "35749543200": {"Name": "Arenaza-Urquijo E.M.", "AuthorID": "35749543200", "AffiliationID": "121846058", "AffiliationName": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES)"}, "57213596584": {"Name": "Gonz\u00e1lez-de-Ech\u00e1varri J.M.", "AuthorID": "57213596584", "AffiliationID": "60023506, 60000100", "AffiliationName": "IMIM (Hospital del Mar Medical Research Institute)"}, "6604034121": {"Name": "Gispert J.D.", "AuthorID": "6604034121", "AffiliationID": "112805675", "AffiliationName": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red Bioingenier\u00eda, Biomateriales y Nanomedicina"}, "24469026000": {"Name": "Su\u00e1rez-Calvet M.", "AuthorID": "24469026000", "AffiliationID": "60023506, 60030315", "AffiliationName": "Servei de Neurologia, Hospital del Mar"}, "6701588028": {"Name": "Molinuevo J.L.", "AuthorID": "6701588028", "AffiliationID": "121846058", "AffiliationName": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES)"}, "57212380582": {"Name": "Simon M.", "AuthorID": "57212380582", "AffiliationID": "113188434", "AffiliationName": "Roche Diagnostics International Ltd"}, "54886040200": {"Name": "Kollmorgen G.", "AuthorID": "54886040200", "AffiliationID": "60072289", "AffiliationName": "Roche Diagnostics GmbH"}, "57208899083": {"Name": "Zetterberg H.", "AuthorID": "57208899083", "AffiliationID": "60022148", "AffiliationName": "UK Dementia Research Institute at UCL"}, "7101909602": {"Name": "Blennow K.", "AuthorID": "7101909602", "AffiliationID": "60031699", "AffiliationName": "Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital"}, "null": {"Name": null, "AuthorID": null, "AffiliationID": null, "AffiliationName": null}}}